Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf (CIO ABCD)

SOP – Mitbetreuung der Angehörigen von Patient:innen mit einer nicht heilbaren Krebserkrankung in der Sterbephase (2024) Oechsle K, Berendt J, Gebert T, Heckel M, Hentschel L, Hornemann B, Jentschke E, et al. Journal article mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) (2024) Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, et al. Journal article NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer (2024) Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, et al. Journal article High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma (2024) Klümper N, Cox A, Eckstein M, Kuppe C, Ritter M, Brossart P, Luetkens J, et al. Journal article Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition (2024) Saal J, Bald T, Eckstein M, Ralser DJ, Brossart P, Ellinger J, Hölzel M, Klümper N Journal article Membranous expression of target protein is required for ADC response in urothelial cancer (2024) Klümper N, Brägelmann J, Bahlinger V, Hartmann A, Grünwald V, Kuppe C, Hölzel M, Eckstein M Journal article On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. (2024) Saal J, Grünwald V, Bald T, Ritter M, Brossart P, Tomita Y, Hartmann A, et al. Journal article Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance (2023) Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, et al. Journal article Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial (2023) Saal J, Bald T, Eckstein M, Ritter M, Brossart P, Ellinger J, Hoelzel M, Klümper N Journal article PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma (2023) Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, et al. Journal article